EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-ND 4.0

The Efficacy of Topical Paromomycin-Gentamicin versus Topical Paromomycin Alone in The Treatment of Cutaneous Leishmaniasis: A meta-analysis of randomized controlled trials

Tareq Alshaikh iD, Mohammed Jihad iD, Awwad Jomaa iD

Sultan Qaboos University Medical Journal · 14.11.2025 · 25 (1) · 1002-1008

DOI: 10.18295/2075-0528.2931 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Sultan Qaboos University Medical Journal, online erschienen am 14.11.2025. Verfasst von Tareq Alshaikh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education and Research, Beit Jala Hospital, Bethlehem, Palestine. Hauptthemen laut MEDLINE: Gentamicins, Leishmaniasis, Cutaneous, Paromomycin. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous leishmaniasis (CL) is the most common protozoal skin infection worldwide. Multiple treatments for CL have been developed to address issues related to resistance, availability, and safety. Topical treatments have shown promise by reducing unnecessary systemic exposure and providing a viable local therapeutic option. A systematic review and meta-analysis were conducted of all literature published before 28 February 2025 through PubMed/MEDLINE, the Cochrane Library, and EBSCO, comparing topical paromomycin–gentamicin (PG) with topical paromomycin alone (PR). Two studies involving a total of 774 patients were included. Relative risks (RRs) from both studies were pooled using a fixed-effect meta-analysis. The meta-analysis showed no significant difference in the final clinical cure of the index lesion between PG and PR (RR = 1.030; 95% confidence interval [CI]: 0.950–1.117), nor in the rate of cure of all lesions (RR = 0.987; 95% CI: 0.909–1.072). No serious adverse events were reported. When treating CL topically, the addition of gentamicin to paromomycin does not confer additional benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GentamicinsLeishmaniasis, CutaneousParomomycinHumansAdministration, TopicalRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Cutaneous LeishmaniasisGentamicinLeishmaniaParomomycinVector Borne Diseases

Substanzen

GentamicinsParomomycin

Autor:innen und Institutionen

  • Department of Medical Education and Research, Beit Jala Hospital, Bethlehem, Palestine.
  • Department of Internal Medicine, Beit Jala Hospital, Bethlehem, Palestine.

ORCID-Profile: Tareq Alshaikh, Mohammed Jihad, Awwad Jomaa

Zitieren

APA

Alshaikh, T., Jihad, M., & Jomaa, A. (2025). The Efficacy of Topical Paromomycin-Gentamicin versus Topical Paromomycin Alone in The Treatment of Cutaneous Leishmaniasis: A meta-analysis of randomized controlled trials. Sultan Qaboos University Medical Journal, 25(1), 1002-1008. https://doi.org/10.18295/2075-0528.2931

Vancouver

Alshaikh T, Jihad M, Jomaa A. The Efficacy of Topical Paromomycin-Gentamicin versus Topical Paromomycin Alone in The Treatment of Cutaneous Leishmaniasis: A meta-analysis of randomized controlled trials. Sultan Qaboos University Medical Journal. 2025;25(1):1002-1008. doi:10.18295/2075-0528.2931

BibTeX
@article{Alshaikh2025,
  author = {Alshaikh, Tareq and Jihad, Mohammed and Jomaa, Awwad},
  title = {The Efficacy of Topical Paromomycin-Gentamicin versus Topical Paromomycin Alone in The Treatment of Cutaneous Leishmaniasis: A meta-analysis of randomized controlled trials},
  journal = {Sultan Qaboos University Medical Journal},
  year = {2025},
  volume = {25},
  number = {1},
  pages = {1002--1008},
  doi = {10.18295/2075-0528.2931}
}
Kostenlos starten →